JO
BBIO icon

John Overdeck’s BridgeBio Pharma BBIO Stock Holding History

John Overdeck’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$352M Buy
4,722,185
+1,601,554
+51% +$112M 0.25% 71
2026
Q1 		$232M Buy
3,120,631
+1,173,584
+60% +$85.1M 0.19% 117
2025
Q4 		$149M Sell
1,947,047
-381,894
-16% -$25.1M 0.21% 117
2025
Q3 		$121M Sell
2,328,941
-10,126
-0.4% -$494K 0.18% 150
2025
Q2 		$101M Buy
2,339,067
+1,495,746
+177% +$54.4M 0.18% 152
2025
Q1 		$29.2M Buy
843,321
+604,785
+254% +$20.4M 0.06% 366
2024
Q4 		$6.55M Sell
238,536
-142,706
-37% -$3.69M 0.01% 952
2024
Q3 		$9.71M Sell
381,242
-184,210
-33% -$4.84M 0.02% 774
2024
Q2 		$14.3M Sell
565,452
-179,148
-24% -$4.9M 0.03% 579
2024
Q1 		$23M Sell
744,600
-222,197
-23% -$7.56M 0.05% 406
2023
Q4 		$39M Sell
966,797
-310,287
-24% -$9.32M 0.09% 268
2023
Q3 		$33.7M Buy
1,277,084
+536,693
+72% +$15.2M 0.09% 263
2023
Q2 		$12.7M Sell
740,391
-39,149
-5% -$589K 0.03% 543
2023
Q1 		$12.9M Buy
779,540
+128,329
+20% +$1.5M 0.04% 498
2022
Q4 		$4.96M Sell
651,211
-219,996
-25% -$2.11M 0.02% 867
2022
Q3 		$8.66M Buy
871,207
+719,944
+476% +$7.48M 0.03% 540
2022
Q2 		$1.37M Sell
151,263
-358,285
-70% -$3M ﹤0.01% 1389
2022
Q1 		$5.17M Sell
509,548
-96,641
-16% -$992K 0.02% 912
2021
Q4 		$10.1M Buy
606,189
+559,467
+1,197% +$23.7M 0.02% 777
2021
Q3 		$2.19M Buy
46,722
+31,043
+198% +$1.66M ﹤0.01% 1907
2021
Q2 		$956K Sell
15,679
-468,149
-97% -$26.7M ﹤0.01% 2507
2021
Q1 		$29.8M Buy
483,828
+319,239
+194% +$20.9M 0.08% 294
2020
Q4 		$11.7M Buy
164,589
+32,414
+25% +$1.56M 0.03% 547
2020
Q3 		$4.96M Buy
+132,175
New +$4.16M 0.02% 798

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

John Overdeck's BBIO Position: Q2 2026 in Review

John Overdeck increased its BridgeBio Pharma (BBIO) stake by 51% in Q2 2026, buying an estimated $112M and bringing the position to 4,722,185 shares worth $352M. The position accounts for 0.25% of the portfolio, ranked #71.

John Overdeck first reported a position in BBIO in Q3 2020 and has held it in 24 quarters since. 471 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • John Overdeck held 4,722,185 shares of BridgeBio Pharma worth $352M as of Q2 2026.
  • John Overdeck bought 1,601,554 BridgeBio Pharma shares in Q2 2026, an estimated $112M.
  • BridgeBio Pharma made up 0.25% of John Overdeck's portfolio in Q2 2026, its #71 holding.
  • John Overdeck first reported a position in BridgeBio Pharma in Q3 2020 and has held it in 24 quarters since.
  • 471 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.